$159.06
10.09% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US85209E1091
Symbol
SPRB

Spruce Biosciences Inc Stock price

$159.06
+149.26 1,523.06% 1M
+149.16 1,506.67% 6M
+127.56 404.95% YTD
+124.02 353.94% 1Y
+69.06 76.73% 3Y
-1,085.94 87.22% 5Y
-965.94 85.86% 10Y
-965.94 85.86% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
-17.85 10.09%
ISIN
US85209E1091
Symbol
SPRB
Industry

Key metrics

Basic
Market capitalization
$89.6m
Enterprise Value
$74.1m
Net debt
positive
Cash
$16.4m
Shares outstanding
560.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
68.9 | 87.8
EV/Sales
57.0 | 72.7
EV/FCF
negative
P/B
6.8
Financial Health
Equity Ratio
63.8%
Return on Equity
-184.0%
ROCE
-368.2%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$1.3m | $1.0m
EBITDA
$-50.6m | $-88.8m
EBIT
$-50.7m | $-39.5m
Net Income
$-48.3m | $-36.4m
Free Cash Flow
$-51.5m
Growth (TTM | estimate)
Revenue
-86.4% | -79.2%
EBITDA
-6.7% | -58.2%
EBIT
-6.7% | 29.6%
Net Income
-12.1% | 31.4%
Free Cash Flow
-3.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,897.9% | -8,704.6%
EBIT
-3,900.4%
Net
-3,721.2% | -3,570.0%
Free Cash Flow
-3,961.1%
More
EPS
$-81.8
FCF per Share
$-91.9
Short interest
1.0%
Employees
9
Rev per Employee
$550.0k
Show more

Is Spruce Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Spruce Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Spruce Biosciences Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Spruce Biosciences Inc forecast:

Hold
50%
Sell
50%

Financial data from Spruce Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1.30 1.30
86% 86%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
4% 4%
1,042%
- Research and Development Expense 38 38
11% 11%
2,955%
-51 -51
7% 7%
-3,895%
- Depreciation and Amortization 0.03 0.03
50% 50%
2%
EBIT (Operating Income) EBIT -51 -51
7% 7%
-3,897%
Net Profit -48 -48
12% 12%
-3,718%

In millions USD.

Don't miss a Thing! We will send you all news about Spruce Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Spruce Biosciences Inc Stock News

Positive
Seeking Alpha
9 days ago
Spruce Biosciences received FDA Breakthrough Therapy Designation for TA-ERT in treating San Filippo Syndrome Type B [MPS IIIB]. BTD enables potential rolling BLA submission, Priority Review, and Accelerated Approval pathway, supported by strong 5-year biomarker and clinical data for TA-ERT. Company plans to file a BLA for TA-ERT for MPS IIIB patients in Q1 2026, aiming to deliver the first dise...
Positive
Barrons
9 days ago
The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation.
Positive
Investors Business Daily
10 days ago
Spruce Biosciences skyrocketed more than 1,600% late Monday after the FDA granted its rare disease drug a breakthrough designation.
More Spruce Biosciences Inc News

Company Profile

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.

Head office United States
CEO Javier Szwarcberg
Employees 9
Founded 2014
Website sprucebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today